Paired box gene 8 - Revision history

Michael: vauthors

2021-03-25T17:13:16Z

vauthors

← Older revision		Revision as of 17:13, 25 March 2021
Line 26:		Line 26:
	*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>		*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>
	**Can help differentiate from lung NETs.		**Can help differentiate from lung NETs.
	*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal \|~~vauthors~~=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>		*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal \|authors=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>

	===May be positive===		===May be positive===
	*Peritoneal [[malignant mesothelioma]] (5 +ve of 27<ref name=pmid28877056>{{cite journal \|~~vauthors~~=Chapel DB, Husain AN, Krausz T, McGregor SM \|title=PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma \|journal=Am. J. Surg. Pathol. \|volume=41 \|issue=12 \|pages=1675–1682 \|date=December 2017 \|pmid=28877056 \|doi=10.1097/PAS.0000000000000935 \|url=}}</ref>).		*Peritoneal [[malignant mesothelioma]] (5 +ve of 27<ref name=pmid28877056>{{cite journal \|authors=Chapel DB, Husain AN, Krausz T, McGregor SM \|title=PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma \|journal=Am. J. Surg. Pathol. \|volume=41 \|issue=12 \|pages=1675–1682 \|date=December 2017 \|pmid=28877056 \|doi=10.1097/PAS.0000000000000935 \|url=}}</ref>).

	==Negative staining==		==Negative staining==
	[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]		[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]
	*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).		*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).
	*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal \|~~vauthors~~=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>		*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal \|authors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>
	*Salivary gland and salivary gland tumours.<ref>{{cite journal \|authors=Butler RT, Alderman MA, Thompson LD, McHugh JB \|title=Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms \|journal=Head Neck Pathol \|volume=9 \|issue=1 \|pages=47–50 \|date=March 2015 \|pmid=24771139 \|pmc=4382472 \|doi=10.1007/s12105-014-0546-4 \|url=}}</ref>		*Salivary gland and salivary gland tumours.<ref>{{cite journal \|authors=Butler RT, Alderman MA, Thompson LD, McHugh JB \|title=Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms \|journal=Head Neck Pathol \|volume=9 \|issue=1 \|pages=47–50 \|date=March 2015 \|pmid=24771139 \|pmc=4382472 \|doi=10.1007/s12105-014-0546-4 \|url=}}</ref>

Michael: /* Negative staining */ salivary gland

2021-02-16T16:13:32Z

Negative staining: salivary gland

← Older revision		Revision as of 16:13, 16 February 2021
Line 36:		Line 36:
	*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal \|vauthors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>		*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal \|vauthors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>
			*Salivary gland and salivary gland tumours.<ref>{{cite journal \|authors=Butler RT, Alderman MA, Thompson LD, McHugh JB \|title=Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms \|journal=Head Neck Pathol \|volume=9 \|issue=1 \|pages=47–50 \|date=March 2015 \|pmid=24771139 \|pmc=4382472 \|doi=10.1007/s12105-014-0546-4 \|url=}}</ref>

	==See also==		==See also==

Mark: wikify PAX5

2020-11-14T12:09:30Z

wikify PAX5

← Older revision		Revision as of 12:09, 14 November 2020
Line 34:		Line 34:
	[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]		[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]
	*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).		*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).
	*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with PAX5)<ref name=pmid22037256>{{cite journal \|vauthors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>		*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal \|vauthors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>

Michael: /* Negative staining */ +mesothelioma

2020-10-03T15:30:00Z

Negative staining: +mesothelioma

← Older revision		Revision as of 15:30, 3 October 2020
Line 27:		Line 27:
	**Can help differentiate from lung NETs.		**Can help differentiate from lung NETs.
	*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal \|vauthors=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>		*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal \|vauthors=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>

			===May be positive===
			*Peritoneal [[malignant mesothelioma]] (5 +ve of 27<ref name=pmid28877056>{{cite journal \|vauthors=Chapel DB, Husain AN, Krausz T, McGregor SM \|title=PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma \|journal=Am. J. Surg. Pathol. \|volume=41 \|issue=12 \|pages=1675–1682 \|date=December 2017 \|pmid=28877056 \|doi=10.1097/PAS.0000000000000935 \|url=}}</ref>).

	==Negative staining==		==Negative staining==

Mark: PAX8 polyclonal antibodies can cross react with PAX5 = false positive

2020-07-05T11:32:46Z

PAX8 polyclonal antibodies can cross react with PAX5 = false positive

← Older revision		Revision as of 11:32, 5 July 2020
Line 31:		Line 31:
	[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]		[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]
	*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).		*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).
	*[[Lymphoma]].		*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with PAX5)<ref name=pmid22037256>{{cite journal \|vauthors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>

Mark: fixed duplicated reference

2020-07-05T11:28:23Z

fixed duplicated reference

← Older revision		Revision as of 11:28, 5 July 2020
Line 26:		Line 26:
	*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>		*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>
	**Can help differentiate from lung NETs.		**Can help differentiate from lung NETs.
	*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115>{{cite journal \|vauthors=Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS \|title=A comprehensive analysis of PAX8 expression in human epithelial tumors \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=6 \|pages=816–26 \|date=June 2011 \|pmid=21552115 \|doi=10.1097/~~PAS.0b013e318216c112 \|url=}}</ref~~><ref name=pmid21836478>{{cite journal \|vauthors=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>		*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal \|vauthors=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>

	==Negative staining==		==Negative staining==

Mark: positive in epithelial component of thymic tumours

2020-07-05T11:27:36Z

positive in epithelial component of thymic tumours

← Older revision		Revision as of 11:27, 5 July 2020
Line 26:		Line 26:
	*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>		*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>
	**Can help differentiate from lung NETs.		**Can help differentiate from lung NETs.
			*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115>{{cite journal \|vauthors=Laury AR, Perets R, Piao H, Krane JF, Barletta JA, French C, Chirieac LR, Lis R, Loda M, Hornick JL, Drapkin R, Hirsch MS \|title=A comprehensive analysis of PAX8 expression in human epithelial tumors \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=6 \|pages=816–26 \|date=June 2011 \|pmid=21552115 \|doi=10.1097/PAS.0b013e318216c112 \|url=}}</ref><ref name=pmid21836478>{{cite journal \|vauthors=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>

	==Negative staining==		==Negative staining==

Michael: /* Negative staining */

2020-06-16T20:06:52Z

Negative staining

← Older revision		Revision as of 20:06, 16 June 2020
Line 29:		Line 29:
	==Negative staining==		==Negative staining==
	[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]		[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]
	*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours.<ref name=pmid21552115/>).		*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).
	*[[Lymphoma]].		*[[Lymphoma]].
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>

Michael at 20:06, 16 June 2020

2020-06-16T20:06:28Z

← Older revision		Revision as of 20:06, 16 June 2020
Line 29:		Line 29:
	==Negative staining==		==Negative staining==
	[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]		[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]
	*[[Urothelial carcinoma]] - can be positive (3/18 bladder tumours).		*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours.<ref name=pmid21552115/>).
	*[[Lymphoma]].		*[[Lymphoma]].
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>

Michael: /* Negative staining */

2020-06-16T20:05:40Z

Negative staining

← Older revision		Revision as of 20:05, 16 June 2020
Line 29:		Line 29:
	==Negative staining==		==Negative staining==
	[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]		[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]
	*[[Urothelial carcinoma]].		*[[Urothelial carcinoma]] - can be positive (3/18 bladder tumours).
	*[[Lymphoma]].		*[[Lymphoma]].
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>

← Older revision		Revision as of 17:13, 25 March 2021
Line 26:		Line 26:
	*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>		*[[Pancreatic neuroendocrine tumour]] ~ 74%.<ref name=pmid20890270>{{Cite journal \| last1 = Sangoi \| first1 = AR. \| last2 = Ohgami \| first2 = RS. \| last3 = Pai \| first3 = RK. \| last4 = Beck \| first4 = AH. \| last5 = McKenney \| first5 = JK. \| last6 = Pai \| first6 = RK. \| title = PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. \| journal = Mod Pathol \| volume = 24 \| issue = 3 \| pages = 412-24 \| month = Mar \| year = 2011 \| doi = 10.1038/modpathol.2010.176 \| PMID = 20890270 }}</ref>
	**Can help differentiate from lung NETs.		**Can help differentiate from lung NETs.
	*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal \|~~vauthors~~=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>		*Epithelial component of thymic tumors 77-100% depending on sub-type<ref name=pmid21552115/><ref name=pmid21836478>{{cite journal \|authors=Weissferdt A, Moran CA \|title=Pax8 expression in thymic epithelial neoplasms: an immunohistochemical analysis \|journal=Am. J. Surg. Pathol. \|volume=35 \|issue=9 \|pages=1305–10 \|date=September 2011 \|pmid=21836478 \|doi=10.1097/PAS.0b013e3182260735 \|url=}}</ref>

	===May be positive===		===May be positive===
	*Peritoneal [[malignant mesothelioma]] (5 +ve of 27<ref name=pmid28877056>{{cite journal \|~~vauthors~~=Chapel DB, Husain AN, Krausz T, McGregor SM \|title=PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma \|journal=Am. J. Surg. Pathol. \|volume=41 \|issue=12 \|pages=1675–1682 \|date=December 2017 \|pmid=28877056 \|doi=10.1097/PAS.0000000000000935 \|url=}}</ref>).		*Peritoneal [[malignant mesothelioma]] (5 +ve of 27<ref name=pmid28877056>{{cite journal \|authors=Chapel DB, Husain AN, Krausz T, McGregor SM \|title=PAX8 Expression in a Subset of Malignant Peritoneal Mesotheliomas and Benign Mesothelium has Diagnostic Implications in the Differential Diagnosis of Ovarian Serous Carcinoma \|journal=Am. J. Surg. Pathol. \|volume=41 \|issue=12 \|pages=1675–1682 \|date=December 2017 \|pmid=28877056 \|doi=10.1097/PAS.0000000000000935 \|url=}}</ref>).

	==Negative staining==		==Negative staining==
	[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]		[[Image:Lymphoma - lung - PAX8 -- intermed mag.jpg\|thumb\|right\|300px\|Negative PAX8 staining in a lymphoma.]]
	*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).		*[[Urothelial carcinoma]] - can be positive (3 positive/18 bladder tumours<ref name=pmid21552115/>).
	*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal \|~~vauthors~~=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>		*[[Lymphoma]] (beware false positive staining due to polyclonal PAX8 antibodies cross-reacting with [[PAX5]])<ref name=pmid22037256>{{cite journal \|authors=Moretti L, Medeiros LJ, Kunkalla K, Williams MD, Singh RR, Vega F \|title=N-terminal PAX8 polyclonal antibody shows cross-reactivity with N-terminal region of PAX5 and is responsible for reports of PAX8 positivity in malignant lymphomas \|journal=Mod. Pathol. \|volume=25 \|issue=2 \|pages=231–6 \|date=February 2012 \|pmid=22037256 \|doi=10.1038/modpathol.2011.162 \|url=}}</ref>
	*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>		*[[Malignant melanoma]].<ref name=pmid21285870>{{Cite journal \| last1 = Tacha \| first1 = D. \| last2 = Zhou \| first2 = D. \| last3 = Cheng \| first3 = L. \| title = Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. \| journal = Appl Immunohistochem Mol Morphol \| volume = 19 \| issue = 4 \| pages = 293-9 \| month = Jul \| year = 2011 \| doi = 10.1097/PAI.0b013e3182025f66 \| PMID = 21285870 }}</ref>
	*Salivary gland and salivary gland tumours.<ref>{{cite journal \|authors=Butler RT, Alderman MA, Thompson LD, McHugh JB \|title=Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms \|journal=Head Neck Pathol \|volume=9 \|issue=1 \|pages=47–50 \|date=March 2015 \|pmid=24771139 \|pmc=4382472 \|doi=10.1007/s12105-014-0546-4 \|url=}}</ref>		*Salivary gland and salivary gland tumours.<ref>{{cite journal \|authors=Butler RT, Alderman MA, Thompson LD, McHugh JB \|title=Evaluation of PAX2 and PAX8 expression in salivary gland neoplasms \|journal=Head Neck Pathol \|volume=9 \|issue=1 \|pages=47–50 \|date=March 2015 \|pmid=24771139 \|pmc=4382472 \|doi=10.1007/s12105-014-0546-4 \|url=}}</ref>